Progenics Pharmaceuticals Inc. (PGNX) Shares Down 1.3%
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)’s share price was down 1.3% on Wednesday . The company traded as low as $6.00 and last traded at $6.10, with a volume of 334,640 shares. The stock had previously closed at $6.18.
A number of equities analysts have recently weighed in on PGNX shares. Jefferies Group reiterated a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. Brean Capital reiterated a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Wednesday, June 15th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 7th. BTIG Research reiterated a “buy” rating and set a $9.00 target price on shares of Progenics Pharmaceuticals in a research note on Wednesday, July 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Progenics Pharmaceuticals in a research note on Friday, July 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $9.95.
The company’s market cap is $436.71 million. The company has a 50-day moving average price of $6.41 and a 200-day moving average price of $5.27.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/progenics-pharmaceuticals-inc-pgnx-shares-down-1-3.html
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.05. The firm had revenue of $8.50 million for the quarter, compared to analysts’ expectations of $6.33 million. Progenics Pharmaceuticals had a negative net margin of 203.56% and a negative return on equity of 41.76%. The business’s quarterly revenue was up 337.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. Equities research analysts forecast that Progenics Pharmaceuticals Inc. will post $0.13 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PGNX. AXA boosted its position in Progenics Pharmaceuticals by 86.5% in the second quarter. AXA now owns 31,900 shares of the company’s stock valued at $135,000 after buying an additional 14,800 shares during the last quarter. BlackRock Investment Management LLC raised its position in shares of Progenics Pharmaceuticals by 5.6% in the second quarter. BlackRock Investment Management LLC now owns 260,867 shares of the company’s stock valued at $1,101,000 after buying an additional 13,853 shares during the period. BlackRock Advisors LLC raised its position in shares of Progenics Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 95,889 shares of the company’s stock valued at $405,000 after buying an additional 1,941 shares during the period. Vanguard Group Inc. raised its position in shares of Progenics Pharmaceuticals by 9.7% in the second quarter. Vanguard Group Inc. now owns 2,737,391 shares of the company’s stock valued at $11,552,000 after buying an additional 241,227 shares during the period. Finally, Princeton Alpha Management LP bought a new position in shares of Progenics Pharmaceuticals during the second quarter valued at about $100,000. 84.22% of the stock is currently owned by hedge funds and other institutional investors.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.